Read + Share
Simon F, Ligtvoet R, Bohn JP, Nosslinger T, et al. Acalabrutinib treatment for older (aged >/=80 years) and/or frail patients with
CLL: primary end point analysis of the CLL-Frail trial. Blood 2025;146:3153-3162.
PMID: 40906922
|
 |
|
Simon F, Ligtvoet R, Bohn JP, Nosslinger T, et al. Acalabrutinib treatment for older (aged >/=80 years) and/or frail patients with
CLL: primary end point analysis of the CLL-Frail trial. Blood 2025;146:3153-3162.
PMID: 40906922
|
|
|
|